Unosi

• Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs (2013-05)

  R. Malmstrom, E. Digene, C. Baumgartel, M. Bennie, I. Bishop, A. Brzezinska, S. Campbell, A. Ferrario, A. Finlayson, J. Furst, K. Garuoliene, M. Gomes, I. Gutierrez-Ibarluzea, A. Haycox, K. Hviding, H. Herholz, M. Hoffman, S. Jan, J. Jones, R. Joppi, M. Kalaba, C. Kvalheim, O. Laius, I. Langner, J. Lonsdale, S. Loov, K. Malinowska, L. McCullagh, K. Paterson, V. Marković Peković, A. Martin, J. Piessnegger, G. Selke, C. Sermet, S. Simoens, C. Tulnay, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wilcock, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs, Frontiers in Pharmacology, Vol. 4, pp. 1 - 31, May, 2013

• Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs (2014-06)

  B. Godman, R. Malmstrom, E. Digene, S. Jayathissa, S. McTaggart, T. Cars, S. Alvarez-Madrazo, C. Baumgartel, A. Brzezinska, A. Bucsics, S. Campbell, I. Eriksson, A. Finlayson, J. Furst, K. Garuoliene, I. Gutierrez-Ibarluzea, K. Hviding, H. Herholz, R. Joppi, R. Joppi, M. Kalaba, O. Laius, K. Malinowska, H. Pedersen, V. Marković Peković, J. Piessnegger, G. Selke, C. Sermet, S. Spillane, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs, Frontiers in Pharmacology, Vol. 5, pp. 1 - 11, Jun, 2014

• Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications (2014-06)

  B. Godman, B. Wettermark, M. van Woerkom, J. Fraeyman, S. Alvarez-Madrazo, C. Berg, I. Bishop, A. Bucsics, S. Campbell, A. Finlayson, J. Furst, K. Garuoliene, H. Herholz, M. Kalaba, O. Laius, J. Piessnegger, C. Sermet, U. Schwabe, V. Vlahović-Palčevski, V. Marković Peković, L. Vončina, K. Malinowska, C. Zara, L. Gustafsson, Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications, Frontiers in Pharmacology, Vol. 5, pp. 1 - 9, Jun, 2014

• Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future (2015-05)

  B. Godman, M. Wilcock, A. Martin, S. Bryson, C. Baumgartel, T. Bochenek, W. de Bruyn, L. Sović-Brkičić, M. D'Agata, A. Fogele, A. Coma Fuste, J. Fraeyman, J. Furst, K. Garuoliene, H. Herholz, M. Hoffman, S. Jayathissa, H. Kwon, I. Langner, M. Kalaba, E. Magnusson, E. Anderse Karlssen, O. Laius, V. Marković Peković, E. Magnusson, S. McTaggart, H. Pedersen, J. Piessnegger, A. Ringerud, G. Selke, C. Sermet, K. Schiffers, P. Skiold, D. Tomek, A. Viksna, A. Vitry, C. Zara, R. Malmstrom, Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future, Generics and Biosimilars Initiative Journal, Vol. 4, No. 3, pp. 125 - 135, May, 2015

• Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future (2016-07)

  W. de Bruyn, C. Ibanez, H. Pedersen, A. Akan, P. Vella Bonanno, L. Sović-Brkičić, A. Bucsics, G. Dedet, J. Eriksen, J. Fadare, J. Furst, G. Gallego, I. Godoi, A. Guerra Junior, H. Gursoz, S. Jan, J. Jones, R. Joppi, S. Kerman, O. Laius, N. Madzikwa, E. Magnusson, M. Maticic, V. Marković Peković, A. Massele, O. Ogunleye, A. O'Leary, J. Piessnegger, C. Sermet, S. Simoens, C. Tiroyakgosi, I. Truter, M. Thyberg, K. Tomek, M. Wladysiuk, S. Vandoros, E. Vural, C. Zara, Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future, Frontiers in Pharmacology, Vol. 7, pp. 1 - 18, Jul, 2016

• Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways (2016-09)

  M. Ermisch, A. Bucsics, P. Vella Bonanno, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Digene, J. Furst, K. Garuoliene, M. van der Graff, J. Gulbinovic, A. Haycox, J. Jones, R. Joppi, O. Laius, I. Langner, A. Martin, V. Marković Peković, L. McCullagh, E. Magnusson, E. Nilsen, G. Selke, C. Sermet, S. Simoens, R. Sauremann, A. Schuurman, R. Ramos, V. Vlahović-Palčevski, C. Zara, B. Godman, Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways, Frontiers in Pharmacology, Vol. 7, pp. 1 - 9, Sep, 2016

• Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation (2017-08)

  P. Vella Bonanno, M. Ermisch, B. Godman, A. Martin, J. Van Den Bergh, L. Bezmelnitsyna, A. Bucsics, F. Arickx, A. Bybau, T. Bochenek, M. van der Casteele, E. Diogene, I. Eriksson, J. Furst, M. Gad, I. Greičiute-Kuprijanov, M. van der Graff, J. Gulbinovic, J. Jones, R. Joppi, M. Kalaba, O. Laius, I. Langner, I. Mardare, V. Marković Peković, E. Magnusson, O. Melien, D. Meshkov, G. Petrova, G. Selke, C. Sermet, S. Simoens, A. Schuurman, R. Ramos, J. Rodrigues, C. Zara, E. Zebedin-Brandl, A. Haycox, Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation, Frontiers in Pharmacology, Vol. 8, pp. 1 - 13, Aug, 2017

• Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018-12)

  B. Godman, A. Bucsics, P. Vella Bonanno, W. Oortwijn, C. Rothe, A. Ferrario, S. Bosselli, A. Hill, A. Martin, S. Simoens, A. Kurdi, M. Gad, J. Gulbinovic, A. Timoney, T. Bochenek, A. Salem, I. Hoxha, R. Sauermann, A. Massele, A. Guerra Junior, G. Petrova, Z. Mitkova, G. Achniotou, O. Laius, C. Sermet, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, M. Oluka, H. Kwon, A. Jakupi, F. Kalemeera, J. Fadare, O. Melien, M. Pomorski, M. Wladysiuk, V. Marković Peković, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, D. Tomek, C. Zara, E. diogene, J. Meyer, R. Malmstrom, B. Wettermark, Z. Matsebula, S. Campbell, A. Haycox, Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets, Frontiers in public health, Vol. 6, No. Article 328, pp. 1 - 21, Dec, 2018

• Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA (2019-02)

  P. Vella Bonanno, A. Bucsics, S. Simoens, A. Martin, W. Oortwijn, J. Gulbinovic, C. Rothe, A. Timoney, A. Ferrario, M. Gad, A. Salem, I. Hoxha, R. Sauremann, M. Kamusheva, M. Dimitrova, G. Petrova, O. Laius, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, A. Jakupi, T. Bochenek, M. Wladysiuk, C. Furtado, V. Marković Peković, I. Mardare, D. Meshkov, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, A. Haycox, S. Campbell, B. Godman, Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 19, No. 3, pp. 251 - 261, Feb, 2019

• Pricing of oral generic cancer medicines in 25 European countries; findings and implications (2019-02)

  B. Godman, A. Hill, S. Simoens, A. Kurdi, J. Gulbinovic, A. Margus, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Hoxha, C. Rodrigues, C. Hierlander, A. Malaj, R. Sauremann, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, G. Selke, J. Yfantopoulos, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. Valk, C. Hagen, A. Ringerud, R. Plisko, M. Wladysiuk, V. Marković Peković, N. Grubiša, T. Ponorac, I. Mardare, T. Novakovic, M. Parker, J. Fraeyman, D. Tomek, M. Obach Cortadellas, C. Zara, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, A. Heycox, Pricing of oral generic cancer medicines in 25 European countries; findings and implications, Generics and Biosimilars Initiative Journal, Vol. 8, No. 2, pp. 49 - 70, Feb, 2019

• The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures (2021-01)

  E. Moorkens, B. Godman, I. Huys, I. Hoxha, A. Malaj, S. Keuerleber, S. Stockinger, S. Mortenhuber, M. Dimitrova, K. Tachkov, L. Vlahović-Palčevski, V. Vlahović-Palčevski, G. Achniotou, J. Slaby, L. Popelkova, K. Kohoutova, D. Bartels, O. Laius, J. Martikainen, G. Selke, V. Kourafalos, E. Magnusson, R. Einarsdottir, R. Adams, R. Joppi, E. Allocati, A. Jakupi, A. Viksna, I. Greičiute-Kuprijanov, P. Vella Bonanno, V. Suttorp, O. Melien, R. Plisko, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, C. Zara, V. Marković Peković, N. Grubiša, G. Befrits, R. Puckett, A. Vulto, The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures, Frontiers in Pharmacology, pp. 1 - 17, Jan, 2021

• Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

  B. Godman, S. Simoens, A. Kurdi, G. Selke, J. Yfantopoulos, A. hill, J. Gulbinovic, A. Martin, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Selke Krulichova, E. Allocati, I. Hoxha, A. Malaj, C. Hierlander, A. Nachtnebel, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, R. Plisko, M. Wladysiuk, V. Marković Peković, I. Mardare, T. Novakovic, M. Parker, J. Furst, D. Tomek, K. Banasova, M. Obach Cortadellas, C. Zara, C. Pontes, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, D. Wong-Rieger, S. Campbell, R. Hill, Variation in the prices of oncology medicines across Europe and the implications for the future, Generics and Biosimilars Initiative Journal, Vol. 10, No. 2, pp. 72 - 82, Feb, 2021

• Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021-03)

  B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichova, C. Zampirolli, A. Martin, W. Oortwijn, A. Timoney, L. Gustafsson, L. Vončina, H. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. da Silva, T. Bochenek, A. Kurdi, E. Allocati, O. Ogunleye, J. Meyer, I. Hoxha, A. Malaj, C. Hierlander, R. Sauremann, W. Hamelinck, G. Petrova, O. Laius, I. Langner, J. Yfantopoulos, R. Joppi, A. Jakupi, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, M. Wladysiuk, V. Marković Peković, I. Mardare, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, C. Pontes, S. McTaggart, T. Laba, O. Melien, D. Wong-Rieger, S. Bae, R. Hill, Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 21, No. 4, pp. 527 - 540, Mar, 2021

• The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future (2021-06)

  B. Godman, M. Haque, T. Leong, E. Allocati, S. Kumar, S. Islam, J. Charan, F. Akter, A. Kurdi, C. Vassalo, M. Abu Bakar, S. Abdur Rahim, N. Sultana, F. Deeba, H. Khan, M. Alam, I. Jahan, Z. Kamal, H. Hasan, M. E-Murshid, S. Nahar, M. Haque, S. Dutta, J. Pallavi Abhayanand, R. Jeet Kaur, G. Rwegerera, R. Nascimento, I. Godoi, M. Irfan, A. Amu, P. Matowa, J. Acolatse, R. Incoom, I. Sefah, J. Acharya, S. Opanga, L. Njeri, D. Kimonge, H. Kwon, S. Bae, K. Khuan, A. Abu Bakar, I. Sani, T. Khan, S. Hussain, Z. Saleem, O. Malande, T. Piloya-Were, R. Gambogi, C. Hernandez Ortiz, L. Alutuli, A. Kalungia, I. Hoxha, V. Marković Peković, B. Tubić, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, M. Wladysiuk, J. Rutkowski, I. Mardare, J. Furst, S. McTaggart, S. MacBride-Stewart, C. Pontes, C. Zara, E. Tagoa, R. Banzi, J. Wale, M. Jakovljevic, The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future, Frontiers in public health, Vol. 9, pp. 1 - 21, Jun, 2021

• Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (2021-10)

  B. Godman, M. Wladysiuk, S. McTaggart, A. Kurdi, E. Allocati, M. Jakovljevic, F. Kalemeera, I. Hoxha, A. Nachtnebel, R. Sauremann, M. Hinteregger, V. Marković Peković, B. Tubić, G. Petrova, K. Tachkov, J. Slaby, R. Nejezchlebova, I. Selke Krulichova, O. Laius, G. Selke, I. Langer, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, J. Gulbinovic, P. Vella Bonanno, J. Rutkowski, S. Ingeberg, O. Melien, I. Mardare, J. Furst, S. McBride-Stewart, C. Holmes, C. Pontes, C. Zara, M. Turu Pedrola, M. Hoffman, V. Kourafalos, A. Pisana, R. Banzi, S. Campbell, B. Wettermark, Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications, BioMed Research International, Vol. 2021, No. Article ID 99961, pp. 1 - 16, Oct, 2021

• Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues (2022-03)

  B. Godman, B. Tubić, E. Allocati, M. Wladysiuk, S. McTaggart, A. Kurdi, M. Haque, S. McBride-Stewart, F. Kalemeera, A. Massele, I. Hoxha, V. Marković Peković, G. Petrova, K. Tachkov, O. Laius, A. Harsanyi, A. Inotai, A. Jakupi, S. Henkuzens, K. Garuoliene, P. Vella Bonanno, J. Rutkowski, I. Mardare, J. Furst, C. Pontes, C. Zara, M. Turu Pedrola, F. Akter, H. Kwon, A. Martin, R. Banzi, J. Wale, J. Gulbinovic, Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues, Journal of Applied Pharmaceutical Science, Vol. 12, No. 3, pp. 055 - 072, Mar, 2022

• Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries (2022-06)

  A. Pisana, B. Wettermark, A. Kurdi, B. Tubić, C. Pontes, C. Zara, E. Van Ganse, G. Petrova, I. Mardare, J. Furst, M. Roig-Izquierdo, O. Melien, P. Vella Bonanno, R. Banzi, V. Marković Peković, Z. Mitkova, B. Godman, Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries, Frontiers in Pharmacology, No. 873556, pp. 1 - 16, Jun, 2022

• Essential To Review Health Policy Initiatives When Comparing Utilisation Patterns across Countries? (2012-08)

  B. Godman, M. Bennie, S. Campbell, K. Garuoliene, M. Kalaba, V. Marković Peković, V. Vlahović-Palčevski, B. Wettermark, C. Zara, L. Gustafsson, Essential To Review Health Policy Initiatives When Comparing Utilisation Patterns across Countries?, Pharmacoepidemiology and Drug Safety Journal 2012; 21: (Suppl. 3), pp. 56 - 56, Aug, 2012